Clinicians who routinely recommend joint supplements to patients have been working with limited options for decades. Glucosamine and chondroitin, the category's default recommendations, have generated a large volume of research, but that research has largely failed to produce consistent, reproducible outcomes. Multiple systematic reviews and meta-analyses have found little or no meaningful benefit compared to placebo, and major clinical bodies have moved away from endorsing these supplements.
The National Center for Complementary and Integrative Health notes that current evidence does not reliably support their use for joint comfort or structural benefit. Against that backdrop, the three published human trials on Cartigenix HP® with RestorCel™ from Calroy Health Sciences represent a meaningful shift in what the published literature can offer.
